^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
OMX-0407
i
Other names: OMX-0407, IMT-07
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
iOmx Therap
Drug class:
SIK3 inhibitor
Related drugs:
3d
A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically (clinicaltrials.gov)
P1/2, N=158, Recruiting, iOmx Therapeutics AG | Phase classification: P1 --> P1/2 | N=30 --> 158 | Trial completion date: May 2025 --> Apr 2026 | Trial primary completion date: Aug 2024 --> Mar 2026
Phase classification • Enrollment change • Trial completion date • Trial primary completion date
|
OMX-0407
1year
Development of a predictive biomarker signature for the highly potent SIK3 inhibitor OMX-0407 (AACR 2023)
By screening sensitive and non-sensitive tumor cell lines and PDX models, we identified a response-prediction biomarker signature. In upcoming clinical studies, this predictive biomarker signature will be evaluated for it’s potential to enrich for patients highly responsive to OMX-0407 therapy.
PD(L)-1 Biomarker • IO biomarker
|
AMPK (Protein Kinase AMP-Activated Catalytic Subunit Alpha 1)
|
OMX-0407
2years
OMX-0407, a highly potent SIK3 inhibitor, sensitizes tumor cells to cell death and eradicates tumors in combination with PD-1 inhibition (AACR 2022)
In summary, OMX-0407, a first-in-class oral SIK3 inhibitor, demonstrates potent monotherapy efficacy in a pro-inflammatory tumor setting by reshaping the immune compartment and accelerating tumor cell death. The ability of OMX-0407 to remodel an immunosuppressed TME in a generally cold tumor setting, harbors great clinical potential for OMX-0407 combination therapy with anti-PD-1/PD-L1 immune checkpoint blockade, specifically in patients with high unmet medical need who are resistant to current immune checkpoint inhibitor monotherapy.
Combination therapy
|
HDAC4 (Histone Deacetylase 4)
|
OMX-0407
Share via
